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Abstract: Studies investigating possible associations between cytochrome P4501B1 (CYP1B1) polymorphisms and breast cancer risk 
have been inconsistent. We set out to ascertain whether there might be an association between polymorphisms in exon 2 (codon 119, 
G→T) and exon 3 (codon 432, G→C) of CYP1B1 and breast cancer in a Chinese Han population in the rural region of Ningxia. Using 
an allele-specific polymerase chain reaction method and direct DNA sequencing, the presence or absence of the two CYP1B1 poly-
morphisms was investigated. Genotype and allele frequencies were analyzed in breast cancer cases (n = 152) and healthy age-matched 
controls (n = 156). The odds ratio (OR) of 119G→T or 432G→C in breast cancer cases and controls was 3.3 (95% CI: 1.28 to 8.28) 
and 2.8 (95% CI: 1.04 to 7.51), respectively. In addition, the OR for people with both polymorphisms (119T and 432C) was 4.69 (95% 
CI: 1.97 to 11.19). Our results suggest that certain polymorphisms in the CYP1B1 gene might increase risk for breast cancer among 
Han Chinese, perhaps because they influence the efficiency of CYP1B1 bio-transformation of oestrogens or pro-carcinogens into DNA-
reactive electrophiles that may act as cancer-initiating agents.
Keywords: breast cancer, CYP1B1, Han population, Ningxia (China), phase I metabolism, polymorphismJiao et al
22  Biomarker Insights 2010:5
Background
Breast  cancer  remains  a  major  cause  of  morbidity 
and mortality worldwide with incidence rates ranging 
from  27/100,000  in Asian  countries  to  97/100,000 
among  US  Causcasian  women,  but  its  aetiology 
remains  unclear.  Only  a  small  proportion  of  cases 
(10%) may be due to germline mutations in highly-
penetrant  susceptibility  genes  e.g.  BRCA1/2.1  The 
majority of cases are sporadic and their causes are 
obscure, although cumulative hormonal exposure and 
environmental influences appear to be risk factors.2,3 
Cytochrome P4501B1 (CYP1B1) catalyzes the for-
mation of genotoxic 4-hydroxy oestradiol (4-OH E2), 
and  bio-activates  environmental  pro-carcinogens 
[e.g. polycyclic aromatic hydrocarbons (PAHs), het-
erocyclic aromatic amines (HAAs)].4–7 The expression 
of CYP1B1 and the formation of 4-OH E2 have been 
associated with oestrogen-related tumours in multiple 
tissues and species.8–10 The 4-OHE2 catechol metabo-
lite has the highest carcinogenic as well as oestrogenic 
activity and is found in higher quantities in breast can-
cer tissue than other 17β-oestradiol (E2) metabolites.11
CYP1B1 is genetically polymorphic, and sequence 
variations in the gene may be related to risk of breast 
cancer in some populations.12–14 The human CYP1B1 
gene, located at the 2p21–22 region, consists of three 
exons, one of which is noncoding, and two introns.15 
Two common polymorphisms of CYP1B1 in exon 2 
(codon 119, Ala→Ser) and exon 3 (codon 432, Val→
Leu) encode the heme-binding domain; variant alleles 
probably exhibit altered activity.6 Therefore, genetic 
polymorphisms at loci encoding CYP1B1 may explain 
why individuals vary in their susceptibility to the car-
cinogenic effects of environmental chemicals.
Studies reporting the association between CYP1B1 
polymorphisms and breast cancer have involved dif-
ferent populations but, have given rise to often incon-
sistent and/or contradicting findings even within the 
same  ethnic  groups.12–14,16–19  We  undertook  a  case-
control study of a genetically-uniform population of 
Han Chinese in the Ningxia Hui Autonomous Region 
of P. R. China in which genotype and allele frequency 
associations  between  CYP1B1  polymorphisms  [in 
exon 2 (codon 119, G→T) and exon 3 (codon 432, 
G→C)] with breast cancer patients and healthy con-
trols were determined. Our results point to an asso-
ciation between these two polymorphisms and breast 
cancer in this study population.
Material and Methods
study participants
From May 2005 to June 2006, a total of 152 sporadic 
breast cancer patients and 156 healthy controls were 
recruited  at Affiliated  Hospital  of  Ningxia  Medi-
cal  University.  All  participants  provided  written 
informed consent before participating in the study. 
This  research  programme  was  approved  by  the 
local  ethics  approvals  board  at  Ningxia  Medical 
University.
The  152  breast  cancer  cases  were  verified  by 
histopathology with a single pathologist. A cohort of 
156 controls confirmed to be free of any cancer based 
on a health examination were randomly matched to 
the breast cancer arm of the study, with an age differ-
ence that was no greater than 5 years (y). The status 
for oestrogen receptor (ER) and progesterone recep-
tor (PR) was also collected. The controls were not 
related in any way with the patients and they had no 
family history of breast cancer. All participants were 
long-term residents of Ningxia who had no prior his-
tory of cancer.
DnA isolation and analysis of single 
nucleotide polymorphisms (snPs)
Blood samples (3–5 ml) were collected in Vacutainer 
tubes  containing  ethylenediaminetetraacetic  acid 
(EDTA). Genomic DNA was extracted using stan-
dard phenol/chloroform methods. The sequences of 
primers for polymerase chain reaction (PCR) at each 
locus were synthesized by SBS-Biology (Beijing) and 
are listed in Table 1.
Polymerase chain reaction (Pcr) 
amplification
Genotyping  assays  for  the  two  SNPs  for  CYP1B1 
were conducted using allele-specific (AS) PCR meth-
ods in a Biometra T Gradient Thermocycler (Bio-Rad 
Laboratories). Each PCR mixture (25 µl) contained 
10 ng DNA, 1 × PCR buffer with 1.5 mmol/L MgCl2, 
0.16  mmol/L  of  each  dNTP,  0.4  µmol/L  of  each 
primer, and 1 unit of Hotstart Taq DNA polymerase 
(SBS-Biology).  The  reaction  mixture  was  initially 
denatured at 95 °C for 5 min, followed by 30 cycles 
at 94 °C for 30 sec, 60 °C for 30 sec, and 72 °C for 
45 sec. The PCR was completed by a final extension 
cycle at 72 °C for 5 min. The DNA fragments were common CYP1B1 polymorphisms in breast cancer
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then separated and visualized by electrophoresis on 
2% agarose gels containing ethidium bromide.
statistical analysis
We determined whether CYP1B1 genotype frequencies 
were in Hardy-Weinberg equilibrium using standard 
χ2-statistics. Odds ratios (ORs) and 95% confidence 
intervals (CIs) were calculated using SPSS (Version 
11.5; Chicago, IL., USA). ORs were used to measure 
the strength of the association between CYP1B1 gen-
otypes and breast cancer risk. The χ2 test was used 
to compare the distributions of CYP1B1 alleles and 
genotypes in cases and controls.
Results
The breast cancer patients had an age range between 
28 y and 75 y, with a mean (M) and standard devia-
tion (SD) of 52.27 (10.28) y. The control cohort had 
an age range between 30 y and 70 y, with a M (SD) of 
52.69 (11.25) y. There was no significant difference 
in the age distribution between the patient and control 
arms of the study.
Representative samples for genotyping codons 119   
and 432 of CYP1B1 are shown in Figures 1A and B, and 
typical sequencing results are shown in Figures 1C 
and D. In tests to determine the genotypes of codon 119 
in CYP1B1, the appearance of only the “a” band was 
identified with GG based on DNA fragment size, the 
appearance of both “a” and “b” bands was identified 
with GT, and the appearance of only a “b” band was 
identified with TT (Fig. 1A). For genotypes of codon 
432 of CYP1B1, the appearance of only the “a” band 
corresponded to GG based on DNA fragment size, the 
appearance of both “a” and “b” bands corresponded 
to GC, and the appearance of only the “b” band corre-
sponded to CC (Fig. 1B). Reverse sequence analysis 
of DNA revealed a heterozygous G→T transition at 
nucleotide 335 of CYP1B1 (GenBank accession No. 
rs1056827), which results in a substitution of alanine 
(Ala) at codon 119 by a serine (Ser) (Fig. 1C). Direct 
sequence analysis of DNA also revealed a heterozy-
gous G→C transition at nucleotide 1294 of CYP1B1 
(GenBank accession No. rs1056836), which causes 
a substitution of the valine (Val) at codon 432 by a 
leucine (Leu) (Fig. 1D).
We compared the distribution frequencies of the 
two  SNPs  for  CYP1B1  in  breast  cancer  patients 
and the controls (Table 2). The frequencies of the 
G and T alleles on codon 119T/G of CYP1B1 differed 
significantly  between  the  two  cohorts  (P  =  0.000) 
with an OR of 2.20 (95% CI: 1.49 to 3.26). The fre-
quencies of G and C alleles on codon 432C/G of 
CYP1B1 also showed significant differences between 
the two cohorts (P = 0.003), with an OR of 1.97 (95% 
CI: 1.25 to 3.11). The genotype frequencies at codons 
119 and 432 for all subjects in this study are shown in 
Table 3. The distributions of the two polymorphisms 
were  consistent  with  Hardy-Weinberg  equilibrium 
(P  0.05). There were significant differences in the 
GG, GT, and TT genotypes between the two cohorts 
(P = 0.001). The risk of breast cancer in individuals 
with genotypes of the homozygous TT mutation and 
heterozygous GT mutation was increased 3.26- and 
2.32-fold, respectively, compared to the risk in indi-
viduals with the wild-type GG. There were significant 
differences in frequencies of the genotype GG, GC, 
CC between the two cohorts (P = 0.038) (Table 3). 
The  risk  of  breast  cancer  in  individuals  with  the 
homozygous CC mutation and the heterozygous GC 
mutation was increased 2.79- and 1.69-fold, respec-
tively, compared to the risk in individuals with the 
wild-type GG.
Table 1. The primer sequences in codons 119 and 432 of CYP1B1.
codon Allele Amino acid primers sequences
119 gcc Ala CYP1B1-119g-F ggccTTcgccgAccggccgg
Tcc ser CYP1B1-119T-F ggccTTcgccgAccggccgT
CYP1B1-119-r gAAgTTgcgcATcATgcTgT
432 CYP1B1-1294-F ATgcgcTTcTccAgcTTTgT
cTg Leu CYP1B1-1294g-r TccgggTTAggccAcTTcAc
gTg Val CYP1B1-1294c-r TccgggTTAggccAcTTcAg
Abbreviations: F, forward primer; r, reverse primer.Jiao et al
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We analyzed the effect of the combined 119/432 
genotypes on breast cancer risk in the Ningxia Han 
population  (Table  4).  In  our  study,  we  observed 
individuals  with  the  genotype  of  119G/G-432C/G, 
119T/T-432C/G, 119G/T-432C/C, or 119G/T-432G/G. 
Therefore it would seem that CYP1B1 codons 119 and 
432 are not in linkage disequilibrium. The OR for 
individuals  possessing  both  119T  and  432C  was 
nearly five times the OR for those possessing 119G/
G-432G/G. No associations were found between these 
two variations and with ER or PR status.20
Discussion
Individual  susceptibility  to  cancer  is  likely  to  be 
influenced by the genotype for enzymes involved in the 
activation or detoxification of carcinogens. Polymorphic 
alleles of key candidate genes such as CYP1B1, which 
are involved in oestrogen and xenobiotic metabolism, 
may contribute to the different risks of breast cancer 
observed for different populations.12–14,16–19 In the pres-
ent study, we investigated CYP1B1 polymorphisms 
in a Ningxia Han Chinese population, and observed 
that the genotypes 119T/T and G/T are present at a 
significantly higher frequency (P = 0.001) in breast 
cancer patients than in control participants. A differ-
ence between breast cancer patients and healthy par-
ticipants was also found in the allelic distributions 
of codon 432. The combination of the two polymor-
phisms  of  CYP1B1  investigated  [in  exon  2  (codon 
119, G→T) and exon 3 (codon 432, G→C)] further 
Figure 1. A, B) representative samples for the genotyping for codons 119 and 432 of CYP1B1; c) reverse sequence analysis to reveal a heterozygous 
g→T transition to result in substitution of Ala at codon 119; and, D) Direct sequence analysis to reveal a heterozygous g→c transition to result in 
substitution of Val at codon 432.
1a 1a
Lane M, 100-bp ladder marker; 1 to 3
represents three different samples with
“a” indicating allele G and “b” allele T.
Lane M, 100-bp ladder marker; 1 to 3
represents three different samples with
“a” indicating allele G and “b” allele C.
A
C
Codon 119, Exon 2
GCC (Ala)
Wild-type Wild-type Variant Variant
Codon 119, Exon 2
GCC (Ala)→TCC (Ser)
Codon 432, Exon 3
GTG (Val)
Codon 432, Exon 3
GTG (Val)→CTG (Leu)
B
D
1b 2a 3a 2b 3b 1b 2a 3a 2b 3b M M
bp bp
400
200
100
400
200
100
Table 2. Association of codons 119 and 432 of CYP1B1 allele with breast cancer risk (han population, ningxia).
Gene Allele no. of case (%) 
(n = 152)
no. of control (%) 
(n = 156)
χ2  
P value
OR (95% cI)
A119s g 217 (71.0) 263 (84.0) 15.5
T 87 (29.0) 49 (16.0) 0.000 2.20 (1.49 to 3.26)
V432L g 245 (80.6) 278 (89.1) 8.78
c 59 (19.4) 34 (10.9) 0.003 1.97 (1.25 to 3.11)common CYP1B1 polymorphisms in breast cancer
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increases the risk of breast cancer in this Ningxia Han 
(China) ethnic group.
Previous studies on the association between CYP1B1 
codon 119(G→T) and codon 432(G→C) and breast 
cancer in different populations have often given rise 
to conflicting or contradicting results. Our results on 
CYP1B1 codon 119(G→T) confirm those of a study in 
a Japanese population.21 Nevertheless, we measured 
higher frequencies of the CYP1B1 codon 119(G→T) 
“T” allele among controls (0.16) and cases (0.29) in 
the Ningxia Han than were reported among controls 
(0.12) and cases (0.16) in the Japanese study.21 There-
fore, CYP1B1 codon 119(G→T), which is thought 
to participate in the substrate recognition site 1 of 
CYP1B1 protein, is significantly associated with breast 
cancer in both the Ningxia Han (China) population 
and the Japanese. This contradicts the protective effect 
reported for this polymorphism in studies carried out 
among Chinese women in Shanghai, Caucasian and 
African  in  U.S.  (Nashville,  Tennessee)  and  Polish 
women.22–24
The valine substitution is reported to be present 
at an allele frequency of 0.43 in Caucasians, 0.75 
in  African-Americans  and  0.23  in  Asians.12,25  No 
association  between  the  CYP1B1 Val432Leu  poly-
morphism and breast cancer was observed in Asians 
(for Val/Val and Val/Leu combined, OR = 1.0, 95% 
CI: 0.8, 1.2). An inverse association was observed 
in a population of mixed/African origin (OR = 0.8, 
95% CI: 0.7, 0.9). The pooled analysis suggested a 
possible association in Caucasians (for Val/Val and 
Val/Leu  combined,  OR  =  1.5,  95%  CI:  1.1,  2.1), 
with effect modification across age categories.26 Our 
finding  of  an  association  between  CYP1B1  codon 
432 (G→C) and breast cancer is consistent with the 
results of several studies in Caucasians.24,26 In our 
study, the risk of breast cancer in individuals with the 
homozygous CC mutation or the heterozygous GC 
mutation was increased 2.79 (95% CI: 1.04 to 7.51)- 
and 1.69 (95% CI: 0.92 to 3.08)-fold, respectively, 
compared to that of individuals with wild-type GG. 
In one study of Caucasians, Listgarten et al26 found 
Table 4. Association between combined CYP1B1 119–432 genotypes and breast cancer (han population, ningxia).
combined  
genotype
no. of case (%)  
(n = 152)
no. of control (%)  
(n = 156)
OR (95%) P value
g/g-g/g 57 (37.5) 93 (59.6) – –
g/g-c/g 19 (12.5) 16 (10.3) 1.94 (0.92 to 4.07) 0.078
g/T-g/g 41 (27.0) 27 (17.3) 2.48 (1.38 to 4.46) 0.002
g/T-c/g 11 (7.2) 5 (3.2) 3.59 (1.19 to 10.86) 0.017
Any T-g/g 52 (34.2) 32 (20.5) 2.65 (1.53 to 4.60) 0.000
Any T-c/g 15 (9.9) 6 (3.8) 4.08 (1.50 to 11.12) 0.004
g/g-any c 25 (16.5) 20 (12.8) 2.04 (1.04 to 4.00) 0.036
g/T-any c 16 (10.5) 7 (4.5) 3.73 (1.45 to 9.62) 0.004
Any T-any c 23 (15.1) 8 (5.1) 4.69 (1.97 to 11.19) 0.000
Table 3. Association of codons 119 and 432 of CYP1B1 genotype with breast cancer risk (han population, ningxia).
Gene Genotype no. of case (%)  
(n = 152)
no. of control (%)  
(n = 156)
χ2  
P value
OR (95% cI)
A119s g/g 80 (52.6) 114 (73.1)
g/T 57 (37.5) 35 (22.4) 14.71 2.32 (1.40 to 3.86)
T/T 15 (9.9) 7 (4.5) 0.001 3.26 (1.28 to 8.28)
V432L g/g 107 (70.4) 128 (82.1)
g/c 31 (20.4) 22 (14.1) 6.55 1.69 (0.92 to 3.08)
c/c 14 (9.2) 6 (3.8) 0.038 2.79 (1.04 to 7.51)Jiao et al
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that the homozygous Leu/Leu mutation conferred a 
3.30-fold higher risk of breast cancer (95% CI: 1.76 
to 6.19), while the heterozygous Val/Leu genotype 
was  associated  with  a  2.15-fold  higher  risk  (95% 
CI: 1.31–3.52). In a study of a Shanghai population, 
Zheng et al18 found that women with the Leu/Leu 
genotype had a 2.3-fold [95% CI, 1.2–4.5] higher risk 
of breast cancer. Our study in the Ningxia Han popu-
lation confirms these results, although we measured 
lower frequencies of the CYP1B1 codon 432(G→C) 
“C”  allele  among  controls  (0.11)  and  cases  (0.19) 
compared to those reported among controls (0.46) and 
cases (0.53) in the Shanghai Han population, respec-
tively. Some studies in Caucasian populations and 
Asian populations19,20,22,27,28 have found no significant 
association between the CYP1B1 Val/Leu genotype 
and breast cancer risk. However, others have found a 
significant increase in the breast cancer risk for smok-
ing women in a Finnish population (OR = 2.6, 95% 
CI 1.07–6.46), especially for smokers homozygous 
for the Leu allele (OR = 5.1, 95% CI 1.30–19.89, 
P for trend = 0.005).13
conclusion
Certain genotypes may contribute to variation in risk 
for breast cancer observed in different populations or 
ethnic groups. To evaluate this in a rural Ningxia Han 
population of P. R. China, we analysed the association 
between CYP1B1 codon 119 (Ala→Ser) and codon 
432 (Val→Leu) and risk of breast cancer. Our results 
show that the risk of breast cancer increases signifi-
cantly (OR = 4.69, 95% CI 1.97–11.9) proportional 
to the number of variant alleles individuals possess. 
Han women living in the Ningxia province are rela-
tively homogeneous in ethnic background, therefore 
eliminating some confounding effects. On the other 
hand, our study investigates a relatively small sam-
ple size in a case-control setting, which may make 
our risk estimates unstable. Nevertheless, our results 
are consistent with recent findings from in vitro and 
animal experiments implicating a potentially impor-
tant role of CYP1B1 in the aetiology of human breast 
cancer.28,29
Other factors such as the expressed profile of ER 
splice variants may play a hitherto under-recognised 
role in the modulation of breast cancer risk.30 How-
ever, we conclude that the functional polymorphism 
of CYP1B1 may be a risk factor for breast cancer in 
the Ningxia Han population of China, and in at least 
some other populations. Further investigations involv-
ing larger sample sizes and other ethnic populations 
are needed in order to establish more completely the 
relationship between these CYP1B1 SNPs and breast 
cancer risk.
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